Bevacizumab for non‐small‐cell lung cancer: A nested case control study of risk factors for hemoptysis - Goto, Koichi; Endo, Masahiro; Kusumoto, Masahiko; Yamamoto, Nobuyuki; Ohe, Yuichiro; Shimizu, Ayaka; Fukuoka, Masahiro (Cancer science, 2016)
Keywords: Aged; Aged, 80 and over; Angiogenesis; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - therapeutic use; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Bevacizumab; Bevacizumab - administration & dosage; Bevacizumab - adverse effects; Bevacizumab - therapeutic use; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Case-Control Studies; Cavitation; Chemotherapy; Clinical trials; Combined Modality Therapy; Drug dosages; Female; Hemoptysis; Hemoptysis - diagnosis; Hemoptysis - epidemiology; Hemoptysis - etiology; Hemorrhage; Humans; Immunotherapy; Incidence; Japanese; Lung cancer; Lung Neoplasms - complications; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Male; Middle Aged; Monoclonal antibodies; Multivariate analysis; Neoplasm Staging; Non-small cell lung carcinoma; non‐small‐cell lung cancer; Original; Patients; Pharmaceuticals; Population Surveillance; Pulmonary arteries; Radiation therapy; real‐world; Respiratory tract; Risk Factors; Targeted cancer therapy; Thorax; Tomography; Tumors; Vascular endothelial growth factor; Veins & arteries; Japan; real-world; hemoptysis; Japanese; Bevacizumab; non-small-cell lung cancer